Jung Won focuses on coverage of all aspects of news in the Korean pharma and biotech industry as well as for regulatory matters. She covers major pharma and biotech conferences in Korea as well as interviewing key opinion leaders. She also handles a regular Korean language podcast on Scrip/Pink Sheet stories. She has worked previously for Dow Jones Newswires, covering various industry sectors and the economy.
Latest from Jung Won Shin
Despite recent setbacks in the field, big pharma still appears to have faith in the tau approach to Alzheimer's, as evidenced by Sanofi's new $1bn-plus deal with Korean venture ADEL for an early stage candidate.
A review of South Korea's GIFT fast track initiative for high-need drugs reveals that foreign firms have been the main beneficiaries over the first three years.
Hanmi Pharm Group announces new mid-term strategy including expansion of its obesity focus to aging with goal of more than doubling revenue by 2030 and becoming a true global player.
Plus deals involving Simcere/Vigonvita, Formosa/Rxilient, Shionogi/Japan Tobacco, Taiho/NEC/JFCR, Toray/Sanodyne, SK Biopharmaceuticals/WARF, BioCorteX/CD Biopharma, ToolGen/GenEditBio and Actimed/Mankind.
South Korea has laid out comprehensive drug pricing reforms that aim to enhance patient access to treatment, accelerate innovation and stabilize essential drug supplies, but the industry is concerned it could lead to weaker R&D and manufacturing and increased dependency on high-priced imports.
The success of AimedBio’s IPO may indicate investors are returning to the South Korean biopharma sector amid a series of large global out-licensing deals by domestic ventures and the strong performance of some recent biotech debutants on Kosdaq.